DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Lidoflazine
Lidoflazine
QT Prolongation Due to Roxithromycin
Ventricular Arrhythmias Associated with Lidoflazine: Side-Effects Observed in a Randomized Trial •Y
Prohibited Substances List
Studies on the Possible Mechanisms of Lidoflazine Arrhythmogenicity
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
Drug Induced Long QT Syndromes: Lethal Reactions to ‘Benign Drugs’ - May/2005 Dr
Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
Anaesthetic Guideline for the Management of Children with Long QT Syndrome SOP/Protocol Detail Owner: Dr
Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
A Unitary Mechanism of Calcium Antagonist Drug Action '(Dihydropyridine/Nifedipine/Verapamil/Neuroleptic/Diltiazem) KENNETH M
Chemically Induced Or Drug Induced Tinnitus
Inherited Heart Conditions Sudden Arrhythmic Death Syndrome
A Computational Tool for Pathway-Based Rational Drug Repositioning Supplementary Information
(12) Patent Application Publication (10) Pub. No.: US 2008/0312247 A1 Gant Et Al
Medications to Avoid in Long QT Syndrome
2021 Equine Prohibited Substances List
New-Drug-Classificat
Florencio Zaragoza Dörwald Lead Optimization for Medicinal Chemists
Top View
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
Development of Phenotypic Assays for Identifying Novel Blockers of L-Type
Marrakesh Agreement Establishing the World Trade Organization
2020 Equine Prohibited Substances List
Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
2019 Equine Prohibited Substances List
The Role of Dental Metal Allergy in Oral Lichen Planus
Therapy of Myeloid Metaplasia-Myelofibrosis, Atypical
NVA237 / Glycopyrronium Bromide Multinational, Multi-Database Cohort
Antiarrhythmic Drugs.Pdf
Relevance of Pre-Clinical Findings for the Interpretation of Adverse Events
Customs Tariff - Schedule Xxi - 1
Inhibition of the HERG Potassium Channel by the Tricyclic Antidepressant Doxepin
Supplementary Information
First-Line Combination Therapy Versus First-Line Monotherapy for Primary Hypertension (Review)
Orlaam and Torsade De Pointes
ACT Annual Meeting
Euregio Laboratory Services MCP Aimed at Horses – Pharmacologic Drug Library
Customs Tariff - Schedule Xxi - 1
Pharmacological Interventions for Hypertensive Emergencies: a Cochrane Systematic Review
Proarrhythmic Assessment of Drugs: the Need for a New Paradigm
Study Protocol Calcium Channel Blocker Treatments and Cancer Risk
Atrial Fibrillation and Hyperthyroidism: a New Look at Their Relationship and Therapy with Lidoflazine K
An Application to Include Blood Pressure Lowering Drug Fixed Dose
A Systematic Review of the Blood Pressure Lowering Efficacy of Calcium Channel Blockers in the Treatment of Primary > Hypertension
ICD-10-CM Table of Drugs 2019
(12) United States Patent (10) Patent No.: US 7,026,360 B1 Fest0 (45) Date of Patent: Apr
(12) United States Patent (10) Patent No.: US 6,572,880 B2 Murdock Et Al
(12) United States Patent (10) Patent No.: US 8,697,361 B2 Johnson (45) Date of Patent: Apr
Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD
Clinical Protocol CA024001
Does Low-Dose Droperidol Administration Increase the Risk of Drug-Induced QT Prolongation and Torsade De Pointes in the General Surgical Population? Gregory A
A Multi-Objective Approach for Drug Repurposing in Preeclampsia
Life with Inherited Abnormal Heart Rhythms
Establishment of Framework for Classification/Categorisation and Labelling of Medicinal Drugs and Driving